Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum Maximum [Member] Federal UNITED STATES Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paidin capital Additional Paid in Capital Purchases of property and equipment and other assets Payments to Acquire Productive Assets Depreciation on equipment Depreciation Impairment of leasehold improvements Impairment of Leasehold Impairment of long-lived assets Total impairment losses Asset Impairment Charges Other assets Impairment of certain other assets Other Asset Impairment Charges Balance Sheets Net loss per share of common stock, basic Earnings Per Share, Basic Amortization of premium and discount on marketable securities, net Amortization of Debt Discount (Premium) Cash and cash equivalents Cash and Cash Equivalent Cash and cash equivalents Cash and Cash Equivalent [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cost or Amortized cost Cash Equivalents, at Carrying Value Certificates of deposit Certificates of Deposit [Member] Valuation allowance increased Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Prepaid expenses and other current assets, and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable, Trade Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Commercial paper Commercial Paper [Member] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Computer hardware Computer Equipment [Member] Corporate debt securities Corporate Debt Securities [Member] Total current liabilities Liabilities, Current Current liabilities: Liabilities, Current [Abstract] Total gross deferred tax assets before valuation allowance Deferred Tax Assets, Gross Research and development credits Deferred Tax Asset, In-Process Research and Development Net deferred taxes Deferred Tax Assets, Net Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Cash accounts in banking institutions Demand Deposits [Member] Net loss per share of common stock, diluted Earnings Per Share, Diluted Foreign pre-tax income or losses Income (Loss) from Continuing Operations before Income Taxes, Foreign Effective tax rate Effective Income Tax Rate Reconciliation, Percent Percent Effective Income Tax Rate Reconciliation, Percent [Abstract] Changes in valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent US federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Other Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Expiration of share-based payment awards Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent [Abstract] Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Share-based compensation expense Share-Based Payment Arrangement, Expense Employee stock purchase plan Employee Stock [Member] Sharebased compensation Share-Based Payment Arrangement, Noncash Expense Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Domestic Tax Jurisdiction [Member] Furniture and fixtures Furniture and Fixtures [Member] Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment General and administrative Total general and administrative expenses General and Administrative Expense General and administrative General and Administrative Expense [Abstract] General and administrative expense General and administrative General and Administrative Expense [Member] Property and equipment, net Impairment expenses for property and equipment Impairment, Long-Lived Asset, Held-for-Use Impairment of property and equipment Impairment of long-lived assets Impairment of Long-Lived Assets to be Disposed of Statements of Operations and Comprehensive Loss Income tax examination, penalties and interest expense Income Tax Examination, Penalties and Interest Expense Accrued interest or penalties related to uncertain tax positions Income Tax Examination, Penalties and Interest Accrued Income Taxes Income Tax Disclosure [Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Amount Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] US federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Other Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Expiration of share-based payment awards Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract] Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Income tax payments Income Taxes Paid, Net Marketable Securities Marketable Securities, Policy [Policy Text Block] Total liabilities Liabilities Total liabilities and stockholders' equity Liabilities and Equity Liabilities and stockholders' equity Liabilities and Equity [Abstract] Amount of loss contingency Loss Contingency Accrual Money market funds Money Market Funds [Member] Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash flows provided by (used in) financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Cash flows provided by (used in) investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Cash flows used in operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Net loss Net loss Net loss Net Income (Loss) Net Income (Loss) Proceeds from the issuance of common stock under employee stock purchase plan Proceeds from Stock Plans Other non-cash items Other Noncash Expense Office equipment Office Equipment [Member] Net operating loss carryforwards Operating Loss Carryforwards Loss from operations Loss from operations Operating Income (Loss) Unrealized gain (loss) on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Other income (expense), net Other (income) expense, net Other Nonoperating Income (Expense) Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Proceeds from issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock under the ATM Facility, net of offering costs Proceeds from Issuance of Convertible Preferred Stock Sales or maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Sales of property and equipment and other assets Proceeds from Sale of Productive Assets Sale of property and equipment and other assets Proceeds from Sale of Property, Plant, and Equipment Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Total property and equipment Property, Plant and Equipment, Gross Property and equipment, net Total, property plant and equipment net Property, Plant and Equipment, Net Property and Equipment, Net Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Purchases of marketable securities Payments to Acquire Marketable Securities Research and Development Research and Development Expense, Policy [Policy Text Block] Research tax credits Research Tax Credit Carryforward [Member] Severance Restructuring and Related Activities Disclosure [Text Block] Unpaid severance Restructuring Reserve Accumulated deficit Retained Earnings (Accumulated Deficit) Sale of Stock [Domain] Schedule of share-based compensation expense category Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Marketable securities Debt Securities, Available-for-Sale, Current Segment Reporting Segment Reporting Disclosure [Text Block] Schedule of reconciliation of reported segment net loss to the statement of operations Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Segment Reporting Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted, Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Unvested balance, Ending Unvested balance, Beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested balance, Weighted average grant date fair value, Beginning Unvested balance, Weighted average grant date fair value, Ending Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested, Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares available for future grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Weighted average grant date fair value of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding, Ending of period Outstanding, Beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, Ending of period Outstanding, Beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Vested and exercisable at December 31, 2025 Vested and exercisable at March 31, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Vested and exercisable at December 31, 2025 Vested and exercisable at March 31, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Award Type [Domain] Share-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] State and Local Jurisdiction [Member] Statements of Cash Flows Statements of Stockholders' Equity Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Issuance cost Payments of Stock Issuance Costs Stockholders' equity: Equity, Attributable to Parent [Abstract] Common Stock Equity [Text Block] Subsequent Event Type [Axis] Subsequent Events Subsequent Event [Line Items] Subsequent Event [Table] Subsequent Event Type [Domain] Sale of Stock [Axis] Supplemental disclosure of noncash activities: Supplemental Cash Flow Information [Abstract] Research tax credits Tax Credit Carryforward, Amount Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward [Axis] Total current assets Assets, Current Current assets: Assets, Current [Abstract] Research and development Research and Development Expense [Abstract] U.S. government securities US Government Debt Securities [Member] Weighted average common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Common stock Common Stock [Member] Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Other Assets Property, Plant and Equipment, Other Types [Member] Leasehold improvements Leaseholds and Leasehold Improvements [Member] Research and development Total research and development expenses Research and Development Expense Fair value Marketable securities Debt Securities, Available-for-Sale Total assets Assets Unrealized gain (loss) on marketable securities Marketable Security, Unrealized Gain (Loss) Income Tax Examination, Description Income Tax Jurisdiction [Domain] Financial Instruments [Domain] Type of Restructuring [Domain] Workforce reduction Employee Severance Employee Severance [Member] Restructuring Cost [Table] Stockholder's Equity and Share-Based Compensation Share-Based Compensation Share-Based Payment Arrangement [Text Block] Fair value Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Statement [Table] Antidilutive Securities, Name [Domain] Assets Assets [Abstract] Statement [Line Items] Operating Loss Carryforwards [Table] Income Taxes Operating Loss Carryforwards [Line Items] Schedule of net operating loss carryforwards Summary of Operating Loss Carryforwards [Table Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Summary of non-financial instruments measured at fair value, on a nonrecurring basis Fair Value Measurements, Nonrecurring [Table Text Block] Property and equipment, net Property, Plant, and Equipment, Fair Value Disclosure Common Stock. Fair Value of Financial Instruments and Non-Financial Instruments Fair Value Disclosures [Text Block] Stockholders' equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Other assets Other Assets, Noncurrent Operating expenses: Operating Expenses [Abstract] Amount of antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Summary of Significant Accounting Policies Per share information: Earnings Per Share [Abstract] Schedule of antidilutive securities excluded from computation of earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Security, Excluded EPS Calculation [Table] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Amortization of premium and discount Investment Income, Net, Amortization of Discount and Premium Property, Plant and Equipment [Table] Long-Lived Assets Held-for-Sale, Name [Domain] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Long-Lived Tangible Asset [Axis] Property, Plant and Equipment [Line Items] Property and Equipment, Net Long-Lived Asset, Held-for-Sale, Type [Axis] Shares available for future issuance Common Stock, Capital Shares Reserved for Future Issuance Total stockholders' equity Balance at Beginning of period Balance at end of period Equity, Attributable to Parent Changes in valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Deferred tax assets: Effective tax rate Income Tax Expense (Benefit) Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2025 and December 31, 2024 Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both March 31, 2026 and December 31, 2025 Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Equity Components [Axis] Additional paidin capital Additional Paid-in Capital [Member] Accumulated deficit Retained Earnings [Member] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Equity Component [Domain] Employee Stock Option Employee Stock Option [Member] Sale of common stock, net of issuance costs Issuance of common stock under the ATM Facility, net of offering costs Stock Issued During Period, Value, New Issues Exercise of stock options and vesting of restricted stock units Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Issuance of shares in connection with employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Shares issued Issuance of common stock under the ATM Facility, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues Exercise of stock options and vesting of restricted stock units (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Issuance of shares in connection with employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Exercised Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Stock issued during period, Reverse stock splits Stock Issued During Period, Shares, Reverse Stock Splits Segments [Axis] Gemma License Agreement Collaborative Arrangement Disclosure [Text Block] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Weighted average remaining contractual term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Vested or expected to vest at December 31, 2025 Vested or expected to vest at March 31, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested or expected to vest at December 31, 2025 Vested or expected to vest at March 31, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Other assets Other Assets, Fair Value Disclosure Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Depreciation and amortization Depreciation and amortization expense Depreciation, Depletion and Amortization Common Stock Class of Stock [Line Items] Stock, Class of Stock [Table] Leases Commitments and contingencies (note 11) Commitments and contingencies (note 10) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Nature of Operations Nature of Operations [Text Block] Accounts payable Accounts Payable, Current Professional fees Accrued Professional Fees, Current Compensation and related benefits Employee-related Liabilities, Current Sharebased compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total financial assets Assets, Fair Value Disclosure Segments [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Measurement Frequency [Domain] Fair Value Hierarchy and NAV [Domain] Recurring Fair Value, Recurring [Member] Nonrecurring basis Fair Value, Nonrecurring [Member] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Nature of Operations Cash, Cash Equivalents, and Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Balance at end of period (in shares) Balance at Beginning of period (in shares) Shares, Outstanding Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Axis] Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of details regarding the Company's portfolio of cash and cash equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Commitments and Contingencies. Income Taxes Fair Value of Financial Instruments and Non-Financial Instruments Subsequent Events Subsequent Events [Text Block] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Schedule of stock option activity plan Schedule of stock option activity plan Schedule of weighted average assumptions applied to options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-Based Compensation Severance Use of Estimates Use of Estimates, Policy [Policy Text Block] Unvested restricted stock units Restricted Stock Units (RSUs) [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Instruments and Non-Financial Instruments Research and development Research and Development Expense [Member] Severance Restructuring Cost and Reserve [Line Items] Restructuring Type [Axis] Summary of Significant Accounting Policies Segment Reporting Subsequent Events. Schedule of details regarding the Company's portfolio of marketable securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Workforce reduction Number of positions eliminated, period percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Commitments and Contingencies Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Income Tax Jurisdiction [Axis] Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Cash and Cash Equivalents [Domain] Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Summary of assets measured at fair value on a recurring basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Forfeited, Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unrecognized compensation expense related to unvested stock option awards Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total unrecognized expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Financial Instrument [Axis] Weighted average exercise price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted-average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Plan Name [Axis] Plan Name [Domain] Award Type [Axis] Cash and Cash Equivalent [Table] Cash and Cash Equivalents [Axis] Cash, cash equivalents and marketable securities Cash and Cash Equivalents [Line Items] Subsequent Event [Member] Subsequent event Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Recently Issued Accounting Pronouncements Not Yet Adopted and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accrued Expenses and Other Current Liabilities Useful life Property, Plant and Equipment, Useful Life Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Vested and exercisable at December 31, 2025 Vested and exercisable at March 31, 2026 Vested or expected to vest at December 31, 2025 Vested or expected to vest at March 31, 2026 Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Weighted average period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of reportable segments Number of Reportable Segments Area leased Area of Land Stock split Stockholders' Equity Note, Stock Split, Conversion Ratio Severance and termination-related expenses Severance Costs Schedule of activity related to restricted stock unit Nonvested Restricted Stock Shares Activity [Table Text Block] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal group classified as held for sale or to be disposed of by sale Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] Total deferred tax liabilities Deferred Income Tax Liabilities, Net Sublease Income Sublease rental income Sublease Income Lease expense Lease, Cost Operating lease cost Operating lease expense Variable lease cost Variable lease expense Net gain on lease termination Net gain on lease termination Gain (Loss) on Termination of Lease Non-refundable sublicense and transition services payments Non-refundable sublicense payments received Contract with Customer, Liability, Current Right of use assets - operating leases Operating Lease, Right-of-Use Asset Future minimum lease payments Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Option to extend lease Lessee, Operating Lease, Existence of Option to Extend [true false] Option to terminate lease Lessee, Operating Lease, Existence of Option to Terminate [true false] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash and cash equivalents at beginning Cash and cash equivalents at end Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Operating lease payments Operating Lease, Payments, Use Right of use assets recognized upon the commencement of sublease Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five 2026 2027 2030 Lessee, Operating Lease, Liability, to be Paid, Year Five 2029 2030 2028 2029 2027 2028 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Schedule of future minimum rental payments for operating leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Impairment expenses for right of use assets Right of use assets Operating Lease, Impairment Loss Total lease liabilities Operating Lease, Liability Operating lease liabilities Operating Lease, Liability, Current Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating lease liabilities - noncurrent Operating Lease, Liability, Noncurrent Summary of operating leases Lease, Cost [Table Text Block] Leasing Lessee, Leases [Policy Text Block] Leases Lessee, Operating Leases [Text Block] Income Tax Examination, Year under Examination Weighted-average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Term of Contract Lessee, Operating Lease, Term of Contract Share-based payment awards Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Share-based payment awards Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent License and Other Revenue Revenue from Contract with Customer [Policy Text Block] Non-refundable sublicense and transition services payments received Increase (Decrease) in Contract with Customer, Liability Renewal term of lease Lessee, Operating Lease, Remaining Lease Term Cover [Abstract] Document Type Amendment Flag Entity Registrant Name Entity Central Index Key Entity Filer Category Entity Small Business Entity Emerging Growth Company No definition available. Gemma License Agreement The entire disclosure of information pertaining to accrued expenses and other current liabilities. Accrued Expenses And Other Current Liabilities Disclosure [Text Block] Accrued Expenses and Other Current Liabilities The carrying balance as of the balance sheet of accrued research and development expense. Accrued Research And Development Expense Research and development Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Divestiture Fees, Current Divestiture fee due to Catalent The carrying balance as of the balance sheet of accrued expenses and other current liabilities. Accrued Expenses and Other Current Liabilities. Accrued expenses and other current liabilities Accrued expenses and other current liabilities Tabular disclosure of information pertaining to accrued expenses and other current liabilities. Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block] Schedule of accrued liabilities and other current liabilities The cash inflow from non-refundable transition service payments received by the company. Proceeds From Non Refundable Transition Services Payments Amount of transition services payments Amount of license fee due and receivable in short-term as of the balance sheet date under the license agreement. Short-Term License Fee Due And Receivable Short-term license fee due and receivables Amount of upfront license fee that is receivable under the license arrangement. Upfront License Fee Receivable Upfront license fee receivable Amount of license fee due and receivable in long-term as of the balance sheet date under the license agreement. Long-Term License Fee Due And Receivable Long-term license fee due and receivables The amount of decrease in payable due to amounts received under transition service payments. Payable, Decrease from Amounts Received Transition Services Payments Transition service payments The cash inflow from non-refundable sublicense payments received. Proceeds From Non-Refundable Sublicense Payments Payment received Represents information pertaining to the arrangement with Gemma Biotherapeutics Inc. Arrangement With Gemma Biotherapeutics Inc [Member] Gemma License Agreement Contingent proceeds upon completing certain business milestones. Contingent Proceeds From Upon Completion of certain business milestones Contingent proceeds upon completing certain business milestones The maximum additional amount in development and commercial milestone payments receivable. Maximum Additional Amount in Development And Commercial Milestone Payments Receivable Maximum additional amount in development and commercial milestone payments receivable The amount of increase (decrease) in prepaid research and development. Increase (Decrease) In Prepaid Research and Development Prepaid research and development The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities. Increase (Decrease) in Right of Use Assets and Operating Lease Liabilities Right of use assets and operating lease liabilities The amount of lease liabilities recognized upon adoption of standard. Operating Lease Liability Recognized Upon Adoption of Standard Operating lease liabilities recognized upon the commencement of sublease Represents information pertaining to Sublease Agreement C. Sublease Agreement C [Member] Sublease Agreement C Represents the operating lease agreement for office space. Operating Leases For Office Space [Member] Operating leases for office space Represents information pertaining to Sublease Agreement A. Sublease Agreement A [Member] Sublease Agreement A Represents the member information pertaining to 1835 Market Street Sublease Agreement. 1835 Market Street Sublease Agreement [Member] 1835 market street sublease agreement Represents information pertaining to Sublease Agreement B. Sublease Agreement B [Member] Sublease Agreement B Represents the operating lease agreement for laboratory space. Operating Leases For Laboratory Space [Member] Operating leases for laboratory space Represents the notice period for termination of lease. Lessee, Operating Lease, Notice Period for Termination of Lease Notice Period for termination lease Represents the percentage of annual increase in sublease rent. Percentage of Annual Increase in Sublease Rent Annual increase in sublease rent (as a percent) Represents the renewal term under new lease agreement. New Lease Agreement, Operating Lease, Renewal Term Extended term of new lease agreement Represents the number of extensions available under the new lease arrangement. New Lease Agreement, Operating Lease, Number Of Extensions Number of extension terms Area subleased. Area Subleased Represents are of land sub leased of the total area under lease. Area of Land subleased, Percentage Subleased area of land Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research And Development Asset, Current Prepaid research and development Disclosure of accounting policy for other income or other expense items. Other Income and Other Expense Policy [Policy Text Block] Other Income (Expense), Net Disclosure of accounting policy for basis of presentation. Basis Of Presentation [Policy Text Block] Basis of Presentation No definition available. Cash, Cash Equivalents, and Marketable Securities No definition available. Risks and Liquidity The entire disclosure of information pertaining to risk and liquidity. Risks And Liquidity [Text Block] Risks and Liquidity Risks, Liquidity, and Going Concern Schedule of information pertaining to risk and liquidity. Risks And Liquidity [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Risks And Liquidity [Line Items] Risks, Liquidity, and Going Concern Represents the member information pertaining to at-the-market (ATM) facility. ATM Facility [Member] ATM Facility Represents information pertaining to property, plant and equipment and certain other assets. Property Plant And Equipment And Certain Other Assets [Member] Property and equipment and certain other assets Represents the information pertaining to Laboratory equipment. Laboratory equipment [Member] Laboratory equipment Represents information pertaining to laboratory equipment and certain other assets. Laboratory Equipment And Certain Other Assets [Member] Laboratory equipment and certain other assets The amount of gain (loss) on sale of tax credits. Gain (Loss) on Sale of Tax Credits Gain (loss) on sale of tax credits Represents information pertaining to stock options (including shares subject to repurchase). Stock options (including shares subject to repurchase) [Member] Stock options Fair value portion of right of use assets. Right of use Assets, Fair Value Disclosure Right of use assets Represents the information pertaining to Computer Hardware and Software. Computer hardware and software. [Member] Computer hardware and software. Represents information pertaining to developing and advancing of genetic medicines. Genetic Medicines Segment [Member] Genetic Medicines Segment Amount of expenses in the period for usage of third party costs attributable to managing and administering the affairs of an entity. General and Administrative, Third Party Costs Third-party costs Amount of expenses in the period for usage of share based compensation attributable to managing and administering the affairs of an entity. General and Administrative, Share Based Compensation Share-based compensation Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit, excluding wages and other benefits incurred for employees in research and development phase of the medicines. General And Administrative, Labor And Related Expenses Wages, benefits, and other payroll Amount of expenses in the period for usage of depreciation and amortization attributable specifically to research and development division. Research and Development, Depreciation and Amortization Depreciation and amortization Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit directly attributable to research and development phase of the medicines. Research And Development, Labor And Related Expenses Wages, benefits, and other payroll Amount of expenses in the period for usage of share based compensation attributable specifically to research and development division. Research and Development, Share Based Compensation Share-based compensation Amount of expenses in the period for usage of depreciation and amortization attributable to managing and administering the affairs of an entity General and Administrative, Depreciation and Amortization Depreciation and amortization Amount of expenses in the period for usage of third party costs attributable specifically to research and development division. Research and Development, Third Party Costs Third-party costs Stockholder's Equity and Share-Based Compensation [Abstract] Additional number of common shares reserved for future issuance. Common Stock, Additional Capital Shares Reserved for Future Issuance Additional number of common shares reserved for future issuance Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement Share Based Payment Arrangement, Percentage Of Outstanding Common Shares As Automatic Increase Percent of the total number of shares of the Company's common stock outstanding Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement. Share Based Payment Arrangement, Period Till Which Automatic Increase In Rights Granted Period till which there is automatic increase in rights granted under the Plan Duration from date of grant (issuance of an option) to when option auto expires. Share-based Compensation Arrangement By Share-based Payment Award Term Term of award Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan. Employee Stock Purchase Plan, Maximum Employee Contribution Percentage Percentage of maximum employee contribution Threshold number of shares that can be purchased in any single offering period. Employee Stock Purchase Plan, Threshold Number Of Shares That Can Be Purchased Number of shares that can be purchased Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan. Employee Stock Purchase Plan, Period Till Which Automatic Increase In Rights Granted Period till which there is automatic increase in rights granted under ESPP The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP. Employee Stock Purchase Plan, Stock Purchase Price Percentage Percentage of stock purchase price Represents the number of equity incentive plans. Number Of Equity Incentive Plans Number of equity incentive plans The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding. Employee Stock Purchase Plan, Maximum Amount Of Common Stock That Can Be Purchased Maximum amount of common stock that can be purchased Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan. Employee Stock Purchase Plan Issuance, Percentage Of Common Stock Outstanding Percentage of common stock outstanding Represents information pertaining to Employee Stock Purchase Plan. Employee Stock Purchase Plan [Member] Employee stock purchase plan Represents information pertaining to Equity Incentive Plan. Equity Incentive Plan [Member] Equity Incentive Plan Represents information pertaining to 2021 Equity Inducement plan. Equity Inducement Plan 2021 [Member] Equity inducement plan 2021 Amount of upfront fees payable per product indication upon developmental milestone. Non - Refundable Fees Payable Per Product Indication Upon Developmental Milestone Non - Refundable fees payable Number of shares agreed to be issued by defendant and subject to reverse stock split. Loss Contingency, Shares Agreed by Defendant Loss contingency, shares agreed by defendant Represents the information pertaining to amended and restated research, collaboration and license agreement with Penn. Amended and restated agreement with Penn [Member] Amended and restated agreement Represents the percentage of target annual bonus amounts. Percentage of Target Annual Bonus Amounts Target annual bonus The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement. Collaboration Agreement Amount Payable Per Product Candidate Upon Achievement Of Specific Development Milestone Amount payable per product candidate upon achievement of specific development milestone Amount of aggregate non-refundable fees payable per product indication. Non - Refundable Aggregate Fees Payable Per Product Indication Non - Refundable aggregate fees payable The amount of payable on sales milestone payment on collaboration and license agreement. Collaboration Agreement Sales Milestone Payments Payable Sales milestone payments The number of stock issued during period for settlement of litigation. Stock Issued During Period, Settlement of Litigation Common stock The amount of payable per product candidate for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement. Collaboration Agreement, Amount Payable Per Product Candidate for Rare Monogenic Disorders, Upon Achievement Of Specific Development Milestone Amount payable per product candidate for rare, monogenic disorders Amount of upfront fees payable per product indication. Non - Refundable Upfront Fees Payable Per Product Indication Non - Refundable upfront fees payable Represents information pertaining to 2020 Equity Incentive Plan. Equity Incentive Plan 2020 [Member] Equity Incentive Plan 2020 The amount of deferred proceeds from sale of equipment in other current assets in non-cash investing or financing transactions. Deferred Proceeds Receivable From Sale Of Equipment In Other Current Assets Deferred proceeds from equipment sale in other current assets No definition available. Risks, Liquidity, and Going Concern [Abstract] Disclosure of accounting policy for interim financial statements. Interim Financial Statements [Policy Text Block] Interim Financial Statements Amount of operating loss carryforward subject to expiry, before tax effects, available to reduce future taxable income under enacted tax laws. Operating Loss Carryforward Subject to Expiration Net operating loss carryforwards subject to expiration Represents the information pertaining to local tax authorities. Local [Member] Local Represents the information pertaining to state tax authorities. State [Member] State Represents the information pertaining to Orphan Drug. Orphan Drug [Member] Orphan drug The remaining capacity of value of shares available to be sold. Remaining Capacity of Value of Shares Available to Be Sold Remaining capacity available to be sold Amount of expense incurred during the period for early lease termination. Early Lease Termination Fee Payment for early lease termination Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee Operating Lease Liability Payments Due After Year Four Thereafter Lease Liability for Operating Lease, Period Decrease due to Lease Termination. Lease Liability For Operating Lease, Period Decrease due to Lease Termination Right of Use period decrease due to lease termination. Right of Use Period Decrease due to Lease Termination Amount of gain (loss) on write-off of assets and liabilities for operating leases. Gain (Loss) On Write Off Of Operating Leases Gain (loss) on write-off of operating leases Amount of license fee due and receivable as of the balance sheet date under the license agreement. License Fee Due And Receivable Amount of license fee due and receivables Amount of cash inflow from short term license. Proceeds From Short Term License Fee Proceeds from short term license fee Amount of aggregate estimated and severance costs to be incurred as a part of restructuring plan. Estimated Severance And Related Costs Estimated severance and related costs Percentage of reduction in workforce as a part of restructuring plan. Restructuring Plan, Reduction In Workforce, Percentage Reduction in workforce The cash outflow related to the payment of lease termination fee. Payment of Lease Termination Fee Payment of lease termination fee Amount of cash payment required to be made by the registrant upon termination of a merger agreement. Merger Agreement Termination Payment Amount Termination payment amount Represents the member information pertaining to 2005 Market Street Lease Agreement. Market Street Lease Agreement 2005 [Member] Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit. Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Percent Orphan drug tax credits Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit. Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount Orphan drug tax credits Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement. Deferred Tax Assets, Collaboration and License Agreement Collaboration and license agreement Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from depreciation and amortization. Deferred Tax Assets, Depreciation and Amortization Depreciation and amortization Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use assets. Deferred Tax Liabilities, Operating Lease Right of Use Assets Right of use assets - operating leases Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities. Deferred Tax Assets Operating Lease Liabilities Operating lease liabilities Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs. Deferred Tax Assets, Capitalized Research and Development Capitalized research and development Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other. Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities and Other Accrued expenses and other